Alere/HIP team up on remote CHF (congestive heart failure) monitoring:
This article was originally published in Clinica
New York health plan HIP has become the first in the eastern US to introduce a remote monitoring system for congestive heart failure (CHF) patients. The system uses Alere Medical technology in a programme that enables doctors to intervene at critical stages by viewing real time information on patient symptoms. CHF affects some 5m people in the US, with new cases being diagnosed at the rate of 400,000 per year. Hospitalisation costs exceed $6bn. A quarter of a million patients die from the condition annually. HIP serves some 800,000 members.
You may also be interested in...
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.